Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation

Mark Fisher, José A. Fernández, Sebastian F. Ameriso, Dangci Xie, Andras Gruber, Annlia Paganini-Hill, John H. Griffin

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background and Purpose: Resistance to activated protein C (APC), a natural plasma anticoagulant, is the most common identifiable risk factor for venous thromboembolic disease. One point mutation in coagulation factor V that renders it APC-resistant is found in >90% of APC-resistant venous thrombosis patients. To determine the prevalence of APC resistance and of this factor V mutation in stroke, we screened a group of ischemic stroke patients. Methods: Hispanic ischemic stroke patients were screened using two different activated partial thromboplastin time-based assays. One assay using neat patient plasma determined APC resistance, and the other assay using patient plasma diluted into factor V-deficient plasma determined APC- resistant factor V, including the Arg506→Gln mutation. Results: were compared with those in 31 Hispanic control subjects of similar ages. Results: Six of 63 (9.5%) stroke patients had APC resistance compared with none of 31 (0%) control subjects. No patient or control subject had APC-resistant factor V, ie, the factor V Arg506→Gln mutation. Conclusions: In Hispanic patients with ischemic stroke, the incidence (approximately 10%) of APC resistance is not caused by the factor V Arg506→Gln mutation. APC resistance not caused by this factor V mutation may be a risk factor for ischemic stroke in this population.

Original languageEnglish (US)
Pages (from-to)1163-1166
Number of pages4
JournalStroke
Volume27
Issue number7
StatePublished - Jul 1996
Externally publishedYes

Fingerprint

Activated Protein C Resistance
Factor V
Stroke
Mutation
Protein C
Hispanic Americans
Partial Thromboplastin Time
R Factors
Point Mutation
Venous Thrombosis
Anticoagulants
Incidence

Keywords

  • cerebral ischemia
  • Hispanic Americans
  • protein C
  • thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Fisher, M., Fernández, J. A., Ameriso, S. F., Xie, D., Gruber, A., Paganini-Hill, A., & Griffin, J. H. (1996). Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation. Stroke, 27(7), 1163-1166.

Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation. / Fisher, Mark; Fernández, José A.; Ameriso, Sebastian F.; Xie, Dangci; Gruber, Andras; Paganini-Hill, Annlia; Griffin, John H.

In: Stroke, Vol. 27, No. 7, 07.1996, p. 1163-1166.

Research output: Contribution to journalArticle

Fisher, M, Fernández, JA, Ameriso, SF, Xie, D, Gruber, A, Paganini-Hill, A & Griffin, JH 1996, 'Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation', Stroke, vol. 27, no. 7, pp. 1163-1166.
Fisher M, Fernández JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A et al. Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation. Stroke. 1996 Jul;27(7):1163-1166.
Fisher, Mark ; Fernández, José A. ; Ameriso, Sebastian F. ; Xie, Dangci ; Gruber, Andras ; Paganini-Hill, Annlia ; Griffin, John H. / Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation. In: Stroke. 1996 ; Vol. 27, No. 7. pp. 1163-1166.
@article{d7abad2149494ee29376619ae2b34fcb,
title = "Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation",
abstract = "Background and Purpose: Resistance to activated protein C (APC), a natural plasma anticoagulant, is the most common identifiable risk factor for venous thromboembolic disease. One point mutation in coagulation factor V that renders it APC-resistant is found in >90{\%} of APC-resistant venous thrombosis patients. To determine the prevalence of APC resistance and of this factor V mutation in stroke, we screened a group of ischemic stroke patients. Methods: Hispanic ischemic stroke patients were screened using two different activated partial thromboplastin time-based assays. One assay using neat patient plasma determined APC resistance, and the other assay using patient plasma diluted into factor V-deficient plasma determined APC- resistant factor V, including the Arg506→Gln mutation. Results: were compared with those in 31 Hispanic control subjects of similar ages. Results: Six of 63 (9.5{\%}) stroke patients had APC resistance compared with none of 31 (0{\%}) control subjects. No patient or control subject had APC-resistant factor V, ie, the factor V Arg506→Gln mutation. Conclusions: In Hispanic patients with ischemic stroke, the incidence (approximately 10{\%}) of APC resistance is not caused by the factor V Arg506→Gln mutation. APC resistance not caused by this factor V mutation may be a risk factor for ischemic stroke in this population.",
keywords = "cerebral ischemia, Hispanic Americans, protein C, thrombosis",
author = "Mark Fisher and Fern{\'a}ndez, {Jos{\'e} A.} and Ameriso, {Sebastian F.} and Dangci Xie and Andras Gruber and Annlia Paganini-Hill and Griffin, {John H.}",
year = "1996",
month = "7",
language = "English (US)",
volume = "27",
pages = "1163--1166",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation

AU - Fisher, Mark

AU - Fernández, José A.

AU - Ameriso, Sebastian F.

AU - Xie, Dangci

AU - Gruber, Andras

AU - Paganini-Hill, Annlia

AU - Griffin, John H.

PY - 1996/7

Y1 - 1996/7

N2 - Background and Purpose: Resistance to activated protein C (APC), a natural plasma anticoagulant, is the most common identifiable risk factor for venous thromboembolic disease. One point mutation in coagulation factor V that renders it APC-resistant is found in >90% of APC-resistant venous thrombosis patients. To determine the prevalence of APC resistance and of this factor V mutation in stroke, we screened a group of ischemic stroke patients. Methods: Hispanic ischemic stroke patients were screened using two different activated partial thromboplastin time-based assays. One assay using neat patient plasma determined APC resistance, and the other assay using patient plasma diluted into factor V-deficient plasma determined APC- resistant factor V, including the Arg506→Gln mutation. Results: were compared with those in 31 Hispanic control subjects of similar ages. Results: Six of 63 (9.5%) stroke patients had APC resistance compared with none of 31 (0%) control subjects. No patient or control subject had APC-resistant factor V, ie, the factor V Arg506→Gln mutation. Conclusions: In Hispanic patients with ischemic stroke, the incidence (approximately 10%) of APC resistance is not caused by the factor V Arg506→Gln mutation. APC resistance not caused by this factor V mutation may be a risk factor for ischemic stroke in this population.

AB - Background and Purpose: Resistance to activated protein C (APC), a natural plasma anticoagulant, is the most common identifiable risk factor for venous thromboembolic disease. One point mutation in coagulation factor V that renders it APC-resistant is found in >90% of APC-resistant venous thrombosis patients. To determine the prevalence of APC resistance and of this factor V mutation in stroke, we screened a group of ischemic stroke patients. Methods: Hispanic ischemic stroke patients were screened using two different activated partial thromboplastin time-based assays. One assay using neat patient plasma determined APC resistance, and the other assay using patient plasma diluted into factor V-deficient plasma determined APC- resistant factor V, including the Arg506→Gln mutation. Results: were compared with those in 31 Hispanic control subjects of similar ages. Results: Six of 63 (9.5%) stroke patients had APC resistance compared with none of 31 (0%) control subjects. No patient or control subject had APC-resistant factor V, ie, the factor V Arg506→Gln mutation. Conclusions: In Hispanic patients with ischemic stroke, the incidence (approximately 10%) of APC resistance is not caused by the factor V Arg506→Gln mutation. APC resistance not caused by this factor V mutation may be a risk factor for ischemic stroke in this population.

KW - cerebral ischemia

KW - Hispanic Americans

KW - protein C

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0029886290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029886290&partnerID=8YFLogxK

M3 - Article

C2 - 8685921

AN - SCOPUS:0029886290

VL - 27

SP - 1163

EP - 1166

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 7

ER -